Preliminary Findings from a Phase 2a Trial of Investigational COVID-19 Therapeutic Molnupiravir
The Pharma Data
MARCH 8, 2021
The totality of the data from these studies indicates that molnupiravir is not mutagenic or genotoxic in in vivo mammalian systems. “We Ridgeback markets EbangaTM for the treatment of Ebola and has a late-stage development pipeline which includes molnupiravir for the treatment of COVID-19. About Molnupiravir.
Let's personalize your content